Short Interest in Precipio, Inc. (NASDAQ:PRPO) Rises By 21.0%

Precipio, Inc. (NASDAQ:PRPO) saw a large growth in short interest in December. As of December 31st, there was short interest totaling 4,991 shares, a growth of 21.0% from the December 15th total of 4,124 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily volume of 8,187 shares, the days-to-cover ratio is currently 0.6 days. Based on an average daily volume of 8,187 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.3% of the company’s stock are short sold.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PRPO. Susquehanna International Group LLP purchased a new stake in shares of Precipio during the 3rd quarter worth approximately $194,000. Topline Capital Management LLC bought a new position in Precipio during the third quarter valued at $1,158,000. Evernest Financial Advisors LLC purchased a new stake in Precipio in the third quarter worth $374,000. Finally, AMH Equity Ltd increased its position in Precipio by 370.1% in the third quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock worth $2,332,000 after buying an additional 103,210 shares during the last quarter. Hedge funds and other institutional investors own 10.45% of the company’s stock.

Precipio Stock Down 2.1%

PRPO traded down $0.50 during mid-day trading on Monday, reaching $23.50. 15,817 shares of the stock were exchanged, compared to its average volume of 6,764. Precipio has a 1 year low of $3.90 and a 1 year high of $28.50. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.10 and a current ratio of 1.27. The stock has a market capitalization of $41.13 million, a PE ratio of -28.66 and a beta of 1.12. The company has a 50 day moving average price of $23.49 and a two-hundred day moving average price of $19.28.

Precipio (NASDAQ:PRPO) last announced its earnings results on Friday, November 14th. The biotechnology company reported ($0.05) EPS for the quarter. Precipio had a negative net margin of 5.50% and a negative return on equity of 10.07%. The firm had revenue of $6.77 million during the quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PRPO. Wall Street Zen cut shares of Precipio from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.